Athira Pharma to Present Overview and Update from ACT-AD

ByLois C

Mar 15, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

BOTHELL, Clean., March 14, 2022 (World NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a late medical-phase biopharmaceutical corporation focused on establishing small molecules to restore neuronal health and fitness and sluggish neurodegeneration, currently introduced that an overview and update of the fully enrolled ACT-Advertisement Stage 2 scientific trial with Athira’s direct growth applicant fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer’s sickness, will be offered at the Worldwide Meeting on Alzheimer’s & Parkinson Diseases™ 2022, Advertisement/PD™ 2022 hybrid​ congress, getting area March 15-20, 2022 just about and in Barcelona.

Presentation Particulars:
Title: Review Structure and Participant Properties of a Phase 2 demo of ATH-1017, a Novel Procedure for Gentle-to-Average Alzheimer’s Disease
Session: Abeta and other targeting therapies in Ad (#113)
Presenter: Hans Moebius, M.D., Ph.D., Main Health care Officer, Athira Pharma, Inc.
Date and Time: Sunday, March 20, 2022, 9:50 a.m. CET
Place: Barcelona, Spain

The presentation slides and an accompanying poster will be out there on the Events and Presentations page of the Investors area of Athira’s site at www.athira.com.

About Fosgonimeton (ATH-1017)
Fosgonimeton (ATH-1017) is a smaller molecule designed to greatly enhance the action of hepatocyte expansion component (HGF) and its receptor, Fulfilled, to influence neurodegeneration and regenerate brain tissue. The perform of the HGF/Achieved receptor system might be impaired in the mind less than conditions of neurodegeneration. Athira is presently analyzing fosgonimeton in numerous clinical trials.

About ACT-Advertisement
ACT-Advertisement is a randomized, double-blind, placebo-managed, parallel-team Stage 2 demo for fosgonimeton (ATH-1017) in topics with delicate-to-average Alzheimer’s sickness. The examine has done enrollment with 77 subjects in the United States and Australia. Research individuals ended up randomized across two dose groups and a single placebo group on a 1:1:1 foundation to get a subcutaneous injection of fosgonimeton or placebo at the time day-to-day around a therapy training course of 26 months. The main endpoint for ACT-Advertisement is Party-Similar-Probable (ERP) P300 Latency, a functional measure of functioning memory processing velocity, and secondary endpoints measuring cognition, function, and behavior. More data on the study can be observed at: https://clinicaltrials.gov/ct2/demonstrate/NCT04491006. The ACT-Advert trial is supported by a grant from the National Institute on Getting old of the Countrywide Institutes of Wellbeing under Award Selection R01AG06268. The facts introduced in this press release and at the Advertisement/PD convention is exclusively the accountability of Athira and does not automatically symbolize the formal sights of the National Institutes of Health.

About Athira Pharma, Inc.
Athira Pharma Inc., headquartered in the Seattle place, is a late scientific-stage biopharmaceutical organization targeted on producing compact molecules to restore neuronal wellness and slow neurodegeneration. Athira aims to give immediate cognitive enhancement and change the system of neurological ailments with its novel system of action. Athira is at this time advancing its direct therapeutic prospect, fosgonimeton, a novel small molecule for Alzheimer’s and Parkinson’s illness dementia and Dementia with Lewy bodies. For more details, visit www.athira.com. You can also observe Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.

Ahead-Seeking Statements
This launch is made up of “forward-on the lookout statements” within the indicating of Portion 27A of the Securities Act of 1933, Segment 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historic reality and incorporate statements concerning fosgonimeton as a possible cure for Alzheimer’s illness, Parkinson’s disease dementia and Dementia with Lewy bodies, and other dementias Athira’s platform technological know-how and potential therapies future development plans medical and regulatory targets and the timing thereof expectations with regards to the possible efficacy and business potential of Athira’s merchandise candidates the expected reporting of knowledge and Athira’s capability to progress its item candidates into afterwards phases of growth. Forward-hunting statements usually include statements that are predictive in nature and depend on or refer to long term gatherings or situations, and incorporate text these kinds of as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” and other similar expressions, among many others. Any ahead-wanting statements are primarily based on management’s present expectations of long run functions and are matter to a variety of dangers and uncertainties that could cause genuine outcomes to differ materially and adversely from those people set forth in or implied by such forward-looking statements. These threats and uncertainties include, but are not constrained to, the preliminary information for Athira’s fosgonimeton product applicant from the Phase 1a/b trials will not keep on or persist in present or prepared clinical trials cessation or delay of any of the ongoing scientific trials and/or Athira’s growth of fosgonimeton and other product or service candidates may happen the impression of the COVID-19 pandemic on Athira’s enterprise, research and medical improvement options and timelines, and the regulatory course of action for Athira product candidates the outcome of authorized proceedings which have been or could in the long run be instituted towards us and certain of our administrators and officers medical trials could not reveal basic safety and efficacy of any of Athira’s product candidates Athira’s assumptions regarding the sufficiency of its cash, dollars equivalents and investments to fund its planned operations may well be incorrect though P300 latency is a purposeful evaluate that is remarkably correlated with cognition, Athira may not correctly build a connection in between these P300 latency effects and improved cognition as well as the other hazards comprehensive in Athira’s filings with the Securities and Trade Fee. These ahead-looking statements talk only as of the day hereof and Athira undertakes no obligation to update ahead-looking statements. Athira may not in fact obtain the programs, intentions, or expectations disclosed in its ahead-wanting statements, and you need to not location undue reliance on the ahead-on the lookout statements.

Investor & Media Contact:
Julie Rathbun
Athira Pharma, Inc.
[email protected]
206-769-9219

By Lois C